Roche Holding AG (RHHBY)
OTCMKTS · Delayed Price · Currency is USD
51.55
+0.35 (0.68%)
Apr 23, 2026, 10:03 AM EST
Roche Holding AG Revenue
In the year 2025, Roche Holding AG had annual revenue of 63.36B CHF with 1.54% growth. Roche Holding AG had revenue of 31.51B in the half year ending December 31, 2025, with 5.64% growth.
Revenue
63.36B CHF
Revenue Growth
+1.54%
P/S Ratio
4.00
Revenue / Employee
613.62K CHF
Employees
103,249
Market Cap
319.71B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 63.36B | 961.00M | 1.54% |
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Vaxart | 237.26M |
| Glass House Brands | 181.98M |
| Elite Pharmaceuticals | 140.12M |
| Tian'an Technology Group | 2.12M |
| Northwest Biotherapeutics | 1.38M |
| Comjoyful International Company | 564.97K |
Roche Holding AG News
- 4 hours ago - Europe risks falling further behind in medicine race, warns Roche CEO - Reuters
- 9 hours ago - Roche CEO laments Swiss franc strength as drugmaker doubles down on U.S. investment - CNBC
- 10 hours ago - Roche Backs Full-Year View as Quarterly Sales Rise - WSJ
- 10 hours ago - Roche Q1 sales down on forex effects - Reuters
- 10 hours ago - [Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc - GlobeNewsWire
- 1 day ago - Roche submits multiple sclerosis drug fenebrutinib to regulators despite patient deaths - Reuters
- 1 day ago - Roche's fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS - GlobeNewsWire
- 1 day ago - Genentech's Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS - Business Wire